548 Odcinki

  1. Addressing the Challenges of Rare Disease Drug Development

    Opublikowany: 7.03.2018
  2. Giving Voice to Patients at the FDA

    Opublikowany: 28.02.2018
  3. Finding a Rare Friend

    Opublikowany: 21.02.2018
  4. Why a Sports Physical May Trigger a Doctor to Think About a Rare Diagnosis

    Opublikowany: 14.02.2018
  5. UPenn's Orphan Disease Center Takes a Rare Approach

    Opublikowany: 7.02.2018
  6. How Patients Can Accelerate Translational Research in Rare Disease

    Opublikowany: 31.01.2018
  7. Notre Dame Center Leverages Commonalities of Rare and Neglected Diseases

    Opublikowany: 24.01.2018
  8. GalXC Quest: Dicerna Bets on Its Unqiue Approach to RNAi

    Opublikowany: 17.01.2018
  9. Pharnext Takes a Unique Twist on Repurposing Drugs for Rare Diseases

    Opublikowany: 10.01.2018
  10. uniQure Seeks to Find Elusive Market Success with Hemophilia B Gene Therapy

    Opublikowany: 3.01.2018
  11. Savara Advances Pipeline of Inhaled Therapeutics for Rare Lung Diseases

    Opublikowany: 27.12.2017
  12. Why the Microbiome May Provide a Novel Approach to Treating Certain Rare Diseases

    Opublikowany: 20.12.2017
  13. FDA Outlines a Collaborative Approach for Pediatric Rare Disease Trials

    Opublikowany: 13.12.2017
  14. Why Patient-Centred Outcomes Are Critical to Rare Disease Drug Trials

    Opublikowany: 6.12.2017
  15. What the FDA's New Framework Means for Regenerative Therapies

    Opublikowany: 29.11.2017
  16. Measuring the Value of Therapies for Ultra-Rare Diseases

    Opublikowany: 22.11.2017
  17. Lessons from Pitching Venture Capitalists

    Opublikowany: 15.11.2017
  18. Health Canada Scraps Plans for Orphan Drug Framework

    Opublikowany: 8.11.2017
  19. New Investment Boosts Rare Disease Drug Accelerator

    Opublikowany: 1.11.2017
  20. Understanding Rare Disease Caregiver Needs

    Opublikowany: 25.10.2017

20 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site